CLINICAL SPOTLIGHT
Uwe Tigör, MD
Chief Medical Officer
"Do we need new medications for better symptom control in chronic stable angina? Medications that not only effectively address symptoms, but also reduce long term cardiovascular risk? Do we need medications that affect not only macro-vascular, but also micro-vascular aspects of chronic angina? Medications that may reduce chronic angina related costs like hospitalizations? At Auxilius Pharma, we believe we do. And we are working on solutions".
We focus on adding clinical value and building strong IP position for all our assets
Our projects have been carefully selected and focus on medicines addressing high unmet clinical needs in cardiology, bringing solutions and value to patients, health care providers, and payers.
AUX-001 Phase 1a results presented at European Society of Cardiology 2024 annual meeting
Phase 1a study explored the safety, tolerability, and pharmacokinetics of AUX-001, which is promising new medication for chronic stable angina. Now that the meeting’s embargo has lifted, we are thrilled to share these results. Click here for more details.
Value-added 505(b)2 Medications
Molecules with well-established clinical efficacy and safety profiles that have undergone some form of modification to improve the product for the benefit of patients, healthcare providers and/or payers are known as Value-added medicines or VAMs. The value is usually added in one of the three areas:
Adapted from: Redesigning Medicines – New Options for Patient-centric Treatment. Sandoz, a Novartis Company.